Confirmation of Interim Results
Tissue Regenix Group plc
("Tissue Regenix" or the "Group")
Confirmation of Interim Results
Investor Presentation
Tissue Regenix (AIM: TRX), the regenerative medical devices company, confirms it will issue its interim results for the six months ended 30 June 2022 on Wednesday 7 September 2022.
Investor Briefing
Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, will be hosting a live online presentation relating to the interim results via the Investor Meet Company platform at 4.30pm on Wednesday 7 September 2022. The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and register for the presentation here: https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor
Investors who already follow Tissue Regenix on the Investor Meet Company platform will automatically be invited.
For more information:
|
Tissue Regenix Group plc David Cocke, Chief Financial Officer |
Via Walbrook PR |
|
|
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison / Nicholas Harland |
Tel: +44(0)20 7710 7600
|
|
Walbrook PR Ltd Alice Woodings / Lianne Applegarth |
Tel: +44 (0)20 7933 8780 TissueRegenix@walbrookpr.com |
|
|
|
About Tissue Regenix (www.tissuergenix.com)
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 15 minutes ago Senior
- 36 minutes ago Me Group International
- 1 hour ago The Global Smaller Companies Trust
- 1 hour ago Niox Group
- 1 hour ago Barclays